Compare HOLX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | EXAS |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 19.7B |
| IPO Year | 1995 | 2000 |
| Metric | HOLX | EXAS |
|---|---|---|
| Price | $75.34 | $103.27 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 18 |
| Target Price | $77.89 | ★ $85.64 |
| AVG Volume (30 Days) | ★ 2.5M | 2.1M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.32 |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $4,100,500,000.00 | $4,144,000.00 |
| Revenue This Year | $4.74 | $15.18 |
| Revenue Next Year | $5.03 | $12.46 |
| P/E Ratio | $95.38 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $51.90 | $38.88 |
| 52 Week High | $75.49 | $103.87 |
| Indicator | HOLX | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 65.17 |
| Support Level | $74.53 | $101.12 |
| Resistance Level | N/A | $103.87 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 85.89 | 66.15 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.